Allon granted U.S. patent for neurotoxicity caused by anti-cancer drugs

30-Mar-2012 - Canada

Allon Therapeutics Inc. announced that it has been granted a U.S. patent that covers the use of the Company’s neuroprotective technology platform in the treatment of peripheral neuropathy. This includes the Company’s lead drug candidate, davunetide, and pipeline product AL-309 as treatments for peripheral neuropathy caused by anti-cancer drugs.

Dr. Alistair Stewart, Allon’s Vice President of Commercial Research, said the Company’s research has shown that its drug candidates are active in preclinical models of peripheral neuropathy, including neurotoxicity and neuropathic pain associated with anti-cancer therapy. “These data lead us to conclude that AL-309 may have the potential to prevent or reduce neurotoxicity when administered in combination with anti-cancer agents known to cause peripheral neurotoxicity and neuropathic pain,” Stewart said.

Allon previously presented preclinical data at a Society for Neurosciences meeting that showed the activity of AL-309 in chemotherapy-induced neuropathy. AL-309, administered in combination with oxaliplatin (an anti-cancer agent) reduced pain symptoms in a model of peripheral neuropathy.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances